Pluviaendo Visuals Pluviaendo Visuals

X
[{"orgOrder":0,"company":"AUM LifeTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM LifeTech Present Preclinical Data on Lung Cancer, PD, and HIV at BIO Digital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"AUM LifeTech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI\/NIH Grant to Advance Their Lung Cancer Immunotherapy Program Using RNA-Targeting Gene Therapy with Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by AUM LifeTech

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            AUM LifeTech's FANA Antisense Oligonucleotide (FANA ASO) RNA silencing approach allows efficient and selective targeting of human FOXP3 at the RNA level, in a highly sequence-specific manner.

            Lead Product(s): Antisense Oligonucleotides

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: National Cancer Institute

            Deal Size: $0.4 million Upfront Cash: Undisclosed

            Deal Type: Funding August 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AUM LifeTech has developed their preclinical pipeline in cancer immunotherapy with a focus on lung cancer using their proprietary RNA targeting technology.

            Lead Product(s): Anitisense Oligonucleotides

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY